EDMONTON, ALBERTA--(Marketwire - Oct. 16, 2007) - ViRexx Medical Corp. (TSX:VIR) (AMEX:REX), a company focused on immunotherapy treatments for certain cancers, chronic hepatitis B & C and embolotherapy treatments for tumors, reports the occurrence of the 118th relapse event in the IMPACT II study. IMPACT II is the second of two identical OvaRex® MAb Phase III trials studying women with stage III or IV advanced ovarian cancer, who had successfully completed front-line therapy. The two Phase III trials, IMPACT I and IMPACT II, were each designed to enroll 177 patients randomized 2 to 1 to receive OvaRex® MAb or placebo. The primary endpoint for each trial is time-to-relapse. IMPACT I reached the 118th relapse event in December 2006 and recently recorded the 134th relapse event.
